CT介入下颈前路靶向注射胶原酶治疗颈椎间盘突出症分析  

The analysis of treatment of cervical disc herniation through anterior approach target-injection of collagenase under CT

作　　者：魏俊[1] 温新院[1] 付敏[1] 刘勇[1] 钟琼[1] 杨俊[1] 

机构地区：[1]赣南医学院第一附属医院疼痛科,赣州341000

出　　处：《中国疼痛医学杂志》2011年第10期604-606,610,共4页Chinese Journal of Pain Medicine

摘　　要：目的：探讨CT介入下颈前路靶向注射胶原酶治疗颈椎间盘突出症的有效性及安全性。方法：126例临床诊断为颈椎间盘突出症患者,在CT介入下经颈前路穿刺达相应椎间盘内,通过纤维环破口及流体力学原理,靶向注射胶原酶200~600u,使胶原酶集中在盘内髓核破损处及突出物处。观察患者术前、术后1、3、7、90、180天视觉模拟评分（VAS）,术后1、3、6月改良Macnab疗效、术后6月突出物缩小程度评定及相关并发症。结果：术后1、3、7、90、180天VAS评分均较术前有显著差异（P〈0.05）,术后1、3、6月改良Macnab疗效优良率分别为86.5%、94.4%、96.8%。术后6月复查91.8%突出物中、重度缩小。结论：CT介入下经颈前路靶向注射胶原酶治疗颈椎间盘突出症疗效可靠,适应症广,安全性高。Objective： To investigate the clinical effects and safety of anterior cervical disc herniation target-injection of collagenase under CT.Methods： 126 patients with cervical disc herniation target-injection of collagenase 200 ~ 600 u under CT through anulus fibrosus laceration.To use collagenase concentrate up-on nucleus pulposas damaged sites and ledges.To observe patients preoperative and postoperative 1,3,7,90 and 180 d with visual analogue scale（VAS）.To evaluate postoperative 1,3,6 month improvement in Macnab therapentic effect.Results： The postoperative 1,3,7,90 and 180 d with visual analogue scale（VAS） showed significant dcrease（P 0.05）.The postoperative 1,3,6 month improvement in Macnab therapentic rate were 86.5%,94.5% and 96.8%,respectively.In 91.8% cases there were moderate or marked decreased in the size of protrution.Conclusion ： Target-injection of collagenase under CT is recom-mended for cervical disc herniation.

关 键 词：颈椎间盘突出症 靶向注射 胶原酶 微创 

分 类 号：R681.53[医药卫生—骨科学]